

## Pharmacy and Therapeutics Advisory Committee Recommendations

September 21, 2006 Meeting

This chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics Advisory Committee at the September 21, 2006, meeting. Review of the recommendations by the Secretary of the Cabinet for Health and Family Services and final decisions are pending.

	<b>Description of Recommendation</b>	<b>P &amp; T Vote</b>
#1	<p><b>Serotonin (5-HT<sub>1</sub>) Receptor Agonists - Triptans</b></p> <ol style="list-style-type: none"> <li>1. All triptans and all dosage forms are considered clinically equivalent in efficacy and safety.</li> <li>2. DMS to select at least 3 branded oral agents with one of those branded oral triptans to include an alternative delivery system to use as preferred based on economic evaluation.</li> <li>3. Imitrex to be available to adolescents via age edit if not selected as a preferred agent.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. Continue monthly quantity limits per manufacturer guidelines with PA required for additional medication.</li> <li>5. Require PA for duplicate therapy/concurrent use of triptans by different routes.</li> <li>6. Implement a continuation of therapy clause which allows patients currently on medications not selected as preferred to continue to receive their medication.</li> <li>7. For any new chemical entity in the triptan class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	<p>Passed 8 - For 0 - Against</p>
#2	<p><b>Anti-Viral Agents, Herpes</b></p> <ol style="list-style-type: none"> <li>1. The antiviral agents for herpes are considered clinically equivalent in efficacy and safety.</li> <li>2. DMS to select acyclovir and at least one branded agent as preferred based on economic evaluation.</li> <li>3. Agents not selected as preferred based on economic evaluation will require PA.</li> <li>4. For any new chemical entity in the class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	<p>Passed 8 - For 0 - Against</p>